Published in Am J Transplant on November 08, 2012
Mortality and cardiovascular disease among older live kidney donors. Am J Transplant (2014) 2.16
Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study. Am J Transplant (2013) 1.34
Consistency of racial variation in medical outcomes among publicly and privately insured living kidney donors. Transplantation (2014) 1.22
Long-term medical risks to the living kidney donor. Nat Rev Nephrol (2015) 1.00
Hospitalizations following living donor nephrectomy in the United States. Clin J Am Soc Nephrol (2014) 1.00
Renal Function Profile in White Kidney Donors: The First 4 Decades. J Am Soc Nephrol (2016) 0.93
Comorbidity burden and perioperative complications for living kidney donors in the United States. Clin J Am Soc Nephrol (2013) 0.89
Emotional well-being of living kidney donors: findings from the RELIVE Study. Am J Transplant (2014) 0.89
Emotional and Financial Experiences of Kidney Donors over the Past 50 Years: The RELIVE Study. Clin J Am Soc Nephrol (2015) 0.81
The association of predonation hypertension with glomerular function and number in older living kidney donors. J Am Soc Nephrol (2014) 0.81
Better understanding live donor risk through big data. Clin J Am Soc Nephrol (2013) 0.81
End-stage renal disease risk in live kidney donors: what have we learned from two recent studies? Curr Opin Nephrol Hypertens (2014) 0.79
Obesity increases the risk of end-stage renal disease among living kidney donors. Kidney Int (2016) 0.78
Increasing the supply of kidneys for transplantation by making living donors the preferred source of donor kidneys. Medicine (Baltimore) (2014) 0.75
Obesity Correlates With Glomerulomegaly But Is Not Associated With Kidney Dysfunction Early After Donation. Transplant Direct (2015) 0.75
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 33.23
Diagnosis and classification of diabetes mellitus. Diabetes Care (2010) 28.34
Long-term consequences of kidney donation. N Engl J Med (2009) 10.17
Perioperative mortality and long-term survival following live kidney donation. JAMA (2010) 7.34
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med (2006) 4.32
20 years or more of follow-up of living kidney donors. Lancet (1992) 3.88
The medical evaluation of living kidney donors: a survey of US transplant centers. Am J Transplant (2007) 3.12
Kidney donors live longer. Transplantation (1997) 2.61
Blood pressure and renal function after kidney donation from hypertensive living donors. Transplantation (2004) 2.22
The state of U.S. living kidney donors. Clin J Am Soc Nephrol (2010) 2.11
Living-donor kidney transplantation: a review of the current practices for the live donor. J Am Soc Nephrol (2005) 1.93
'Normal for now' or 'at future risk': a double standard for selecting young and older living kidney donors. Am J Transplant (2010) 1.90
Cardiovascular disease and hypertension risk in living kidney donors: an analysis of health administrative data in Ontario, Canada. Transplantation (2008) 1.83
Long-term (20-37 years) follow-up of living kidney donors. Am J Transplant (2002) 1.70
Substantial variation in the acceptance of medically complex live kidney donors across US renal transplant centers. Am J Transplant (2008) 1.57
Renal outcome 25 years after donor nephrectomy. J Urol (2001) 1.47
Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review. Am J Transplant (2008) 1.36
Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant (2005) 1.20
The risks of unilateral nephrectomy: status of kidney donors 10 to 20 years postoperatively. Mayo Clin Proc (1985) 1.03
Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant (2006) 8.03
Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology (2001) 6.82
20 years or more of follow-up of living kidney donors. Lancet (1992) 3.88
Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int (2006) 3.58
Limiting financial disincentives in live organ donation: a rational solution to the kidney shortage. Am J Transplant (2006) 3.31
Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst (1993) 3.05
Report of a National Conference on Donation after cardiac death. Am J Transplant (2006) 3.04
Survival benefit-based deceased-donor liver allocation. Am J Transplant (2009) 2.89
Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int (2006) 2.85
Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol (2001) 2.80
Identifying specific causes of kidney allograft loss. Am J Transplant (2008) 2.77
Pregnancy outcomes after kidney donation. Am J Transplant (2009) 2.66
Effect of waiting time on renal transplant outcome. Kidney Int (2000) 2.57
The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant (2008) 2.48
Organ donation in three major American cities with large Latino and black populations. Transplantation (1988) 2.41
Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant (2008) 2.39
Long-term survival in renal transplant recipients with graft function. Kidney Int (2000) 2.38
Determinants of discard of expanded criteria donor kidneys: impact of biopsy and machine perfusion. Am J Transplant (2008) 2.38
Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant (2013) 2.35
Organ donation and utilization in the United States, 1999-2008. Am J Transplant (2010) 2.33
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation (1993) 2.20
Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther (1997) 2.17
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
Database comparison of the adult-to-adult living donor liver transplantation cohort study (A2ALL) and the SRTR U.S. Transplant Registry. Am J Transplant (2010) 2.04
Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant (2008) 2.04
Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant (2010) 2.02
American Society of Transplant Surgeons transplant center outcomes requirements--a threat to innovation. Am J Transplant (2009) 2.00
Transplantation of discordant xenografts: a review of progress. Immunol Today (1990) 2.00
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Mortality after kidney transplantation: a comparison between the United States and Canada. Am J Transplant (2006) 1.92
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation (2000) 1.90
Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg (2001) 1.89
Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant (2006) 1.83
Increased incidence of malignancy during chronic renal failure. Lancet (1975) 1.79
Geographic variability in access to primary kidney transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.77
Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation (2001) 1.73
First-pass metabolism of cyclosporin by the gut. Lancet (1991) 1.71
Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant (2006) 1.70
Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study. Am J Transplant (2008) 1.69
Recovery and utilization of deceased donor kidneys from small pediatric donors. Am J Transplant (2006) 1.68
CYP3A gene expression in human gut epithelium. Pharmacogenetics (1994) 1.66
Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation (1995) 1.65
Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science (1976) 1.65
Long-term follow-up of living kidney donors: quality of life after donation. Transplantation (1999) 1.65
Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant (2010) 1.65
Geographic differences in event rates by model for end-stage liver disease score. Am J Transplant (2006) 1.62
Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology (1992) 1.62
Complications and risks of living donor nephrectomy. Transplantation (1997) 1.61
Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant (2015) 1.61
Quality of life in newly diagnosed glaucoma patients : The Collaborative Initial Glaucoma Treatment Study. Ophthalmology (2001) 1.61
The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology (2001) 1.60
Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int (2007) 1.60
The riskiest job in medicine: transplant surgeons and organ procurement travel. Am J Transplant (2009) 1.58
The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol (1996) 1.58
Randomized controlled trial of hand-assisted laparoscopic versus open surgical live donor nephrectomy. Transplantation (2001) 1.58
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant (2010) 1.56
A double-blind, randomized, placebo-controlled trial of prostaglandin E1 in liver transplantation. Hepatology (1995) 1.56
Preoperative risk factor assessment in liver transplantation. Surgery (1992) 1.55
Dynamic challenges inhibiting optimal adoption of kidney paired donation: findings of a consensus conference. Am J Transplant (2013) 1.55
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother (2000) 1.50
Repeat organ transplantation in the United States, 1996-2005. Am J Transplant (2007) 1.50
Evaluation of living renal donors. The current practice of US transplant centers. Transplantation (1995) 1.47
Colon perforation after renal transplantation: a single-institution review. Clin Transplant (1997) 1.47
Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant (2010) 1.47
Utilization of kidneys with similar kidney donor risk index values from standard versus expanded criteria donors. Am J Transplant (2012) 1.46
Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation (1989) 1.46
Satisfaction With Life Among Living Kidney Donors: A RELIVE Study of Long-Term Donor Outcomes. Transplantation (2014) 1.45
Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery (1977) 1.45
Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant (2009) 1.44
Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant (2006) 1.42
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
First things first: laying the ethical and factual groundwork for living kidney donor selection standards. Am J Transplant (2008) 1.40
Uremic pericardial effusion. Treatment by catheter drainage and local nonabsorbable steroid administration. Nephron (1976) 1.39
Access and outcomes among minority transplant patients, 1999-2008, with a focus on determinants of kidney graft survival. Am J Transplant (2010) 1.38
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant (2008) 1.37
Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation (1998) 1.35
Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg (1980) 1.34
Health-related quality of life in kidney donors from the last five decades: results from the RELIVE study. Am J Transplant (2013) 1.34
The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant (2008) 1.33
Complications of living donor hepatic lobectomy--a comprehensive report. Am J Transplant (2012) 1.32
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Human islet autotransplantation following pancreatectomy. Transplant Proc (1979) 1.30
Transplant glomerulopathy. Am J Transplant (2008) 1.29
Pancreatic islet cell transplantation. Surg Clin North Am (1978) 1.28
An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation (1996) 1.27
Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant (2008) 1.27
Seven years' experience with antilymphoblast globulin for renal transplantation from cadaver donors. Ann Surg (1976) 1.26
Transplantation of pediatric donor kidneys to adult recipients. Is there a critical donor age? Ann Surg (1986) 1.26